Overview:

The subcutaneous immunoglobulin are the biologic molecules that are injected subcutaneously for the cure of certain diseases/disorders such as infectious diseases, immune deficiencies, and bleeding disorders among others. Due to patient compliance the preference of subcutaneous immunoglobulin is rising over the intravenous route of administration. The global subcutaneous immunoglobulin market expected to witness a lucrative growth during the forecast period owing to the growing burden of primary immunodeficiency diseases, rising geriatric population and opportunities for immunoglobulins for secondary immunodeficiency diseases treatment.

The global subcutaneous immunoglobulin market is segmented based on the application, end-users, and geography. Based on the application, the global subcutaneous immunoglobulin market is segmented into secondary immunodeficiency diseases, primary immunodeficiency diseases, and others diseases. Others segment include neurological disorders, infectious diseases, bleeding disorders etc. In 2017, the primary immunodeficiency diseases segment dominated the global market owing to the growing prevalence such diseases and surging research and developments. Based on the end-users, the global market is segmented into home care, hospitals, and clinics. In 2017, the hospitals segment led the market and homecare segmented is identified as the fastest growing segment. The preference of the patient and ease of use for the subcutaneous immunoglobulin administration accounted for the rapid growth of the homecare segments.

In 2017, the North America accounted for the major share in global subcutaneous immunoglobulin market owing to the rise in geriatric population, technological advancements and initial launch of products. According to the U.S. Census Bureau, the population equal to and above 60 years of age in United States will rise to 12.67% in 2026 from 10.90%, which indicates the high demand of subcutaneous immunoglobulin during the forecast period. According to the Immune Deficiency Foundation, in 2015, an approximate of 55,000 patients in the United States were treated with primary immunodeficiency diseases and the cases are expected to grow during the forecast period.

The manufacturers are competing heavily in the market based on the pricing and the approaches to effectively deliver the immunoglobulin in the patient’ body. For instance, Shire Plc has developed a product, Hyquia, which consist of dual vial unit, one for immunoglobulin infusion 10% and another for recombinant human hyaluronidase. The simultaneous subcutaneous administration of both the formulations enhances the bioavailability of the immunoglobulin and allows infusion of large volume.

The Global Subcutaneous Immunoglobulin (SCIg) Market is segmented on the following bases:

• Global Subcutaneous Immunoglobulin (SCIg) Market, by Application, 2016-2026 (US$ Mn)
  • Primary Immunodeficiency Diseases
  • Secondary Immunodeficiency Diseases
  • Others (Neurological Disorders, Infectious Diseases, Bleeding Disorders etc.)
• Global Subcutaneous Immunoglobulin (SCIg) Market, by End-users, 2016-2026 (US$ Mn)
  • Hospitals
  • Homecare
  • Clinics
• Global Subcutaneous Immunoglobulin (SCIg) Market, by Geography, 2016-2026 (US$ Mn)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Rest of Middle East & Africa

Key Players Identified in Subcutaneous Immunoglobulin (SCIg) Market include:

Baxalta Incorporated, Biotest AG, CSL Behring, LLC, Grifols S.A., Kedrion S.p.A., Octapharma AG, Shire Plc, and Talecris Biotherapeutics, Inc.

This report offers:

• The prominent end-users for subcutaneous immunoglobulin (SCIg) across geographies.
• The regional market comparison for subcutaneous immunoglobulin and the most attractive region for expanding geographical outreach or product launch.
• The current trends in subcutaneous immunoglobulin market at the granular level
• Market sizing of the global subcutaneous immunoglobulin market for the span of 10 years from 2016 to 2026 and quantifies the growth of the market during the forecast period.
• Mapping of the players based on the product offering, business strengths, strategic initiatives, product launches, geographical expansion and profiling of major players